Scenic Biotech, a pioneer in the field of modifier therapies for severe genetic disorders, has entered into a research collaboration with Bristol Myers Squibb to accelerate the development of Bristol Myers Squibb’s drug targets by identifying target biology for indication selection and expansion.   Per the terms of the agreement, Scenic Biotech will be entitled to an upfront payment and potential additional payments contingent upon achievement of a range of research, development and commercial...